New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
08:11 EDTACADACADIA to get funding from Fast Forward, EMD Serono for MS program
ACADIA Pharmaceuticals announced that it will receive funding from Fast Forward, a not-for-profit organization established by the National Multiple Sclerosis Society, and EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany. This funding will support ACADIA research, to be conducted in collaboration with Dr. Rhonda Voskuhl of UCLA, directed at using AC-186, ACADIAís proprietary and selective estrogen receptor-beta agonist, as a new approach to the treatment of multiple sclerosis. Fast Forward and EMD Serono will provide up to $545,000 to support preclinical studies with AC-186 designed to further evaluate pharmacokinetics and its therapeutic potential in preclinical models of MS. This funding will be provided by the partiesí Accelerating Commercial Development Fund, which is allocated to for-profit entities and is designed to accelerate the development of research discoveries into new or improved therapies for people with MS.
News For ACAD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
09:17 EDTACADOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTACADACADIA initiated with an Outperform at Cowen
Target $46.
November 20, 2014
09:29 EDTACADACADIA management to meet with Piper Jaffray
Meetings to be held in Europe November 27 and 28 Piper Jaffray.
November 18, 2014
07:21 EDTACADUBS to hold a field trip
Subscribe for More Information
November 17, 2014
19:01 EDTACADACADIA management to meet with Piper Jaffray
Subscribe for More Information
November 11, 2014
09:13 EDTACADACADIA NDA filing delay minor, says JMP Securities
Subscribe for More Information
07:13 EDTACADACADIA filing delay does not impact price target, says Piper Jaffray
Subscribe for More Information
November 10, 2014
18:32 EDTACADOn The Fly: After Hours Movers
Subscribe for More Information
16:05 EDTACADACADIA delays NUPLAZID application to Q1 of 2015
ACADIA said it plans to submit its NUPLAZID NDA for Parkinson's disease psychosis in Q1 of 2015. The company had previously planned to submit the NDA near the end of 2014. It stated, "The decision to move back the planned submission is based on additional time required to complete preparations needed to support the U.S. Food and Drug Administrationís, review of NUPLAZID. The change in submission timing is not a result of any change to NUPLAZIDís clinical or safety profile, nor is it a result of any interaction with or request for information from the FDA. Additionally, ACADIA reported that it has successfully completed its drug-drug interaction program and its registration stability program."
16:04 EDTACADACADIA reports Q3 EPS (25c), consensus (22c)
At September 30, 2014, ACADIAís cash, cash equivalents, and investment securities totaled $337.8M.
15:26 EDTACADNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use